Robert Wesolowski

20PUBLICATIONS
166CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Sep 29, 2026
Episodic Future Thinking: A Behavioral Intervention to Promote Weight Loss in Breast Cancer Survivors (Alliance A21-Pilot10).

|Mar 09, 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Sara A Hurvitz, Rachel M Layman, Giuseppe Curigliano

|Jul 25, 2025
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.

Robert Wesolowski, Hope S Rugo, Jennifer M Specht

|Jun 12, 2025
Impact of low hormone receptor expression on neoadjuvant chemotherapy response and patterns of care in non-metastatic HER2-negative breast cancer: a US National Cancer Database analysis.

Dionisia Quiroga, Charles Pei, Julie A Stephens

|Sep 12, 2024
A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas.

Olivier Rixe, John L Villano, Robert Wesolowski

|Jun 19, 2024
The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer.

Kai C C Johnson, Ai Ni, Dionisia Quiroga

Pageof 4

Frequent Collaborators

7 joint publications

Bhuvaneswari Ramaswamy

7 joint publications

Maryam Lustberg

7 joint publications

Daniel Stover

7 joint publications

Anne Noonan